Spanish pharmacy study reports 12 kg mean loss on GLP-1 and GIP/GLP-1 agonists
Across 531 patients enrolled at community pharmacies, mean weight fell 11.71% from a baseline that patients reported retrospectively rather than from clinical records.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 7 20:00 ETSource: Healthcare (Basel, Switzerland)
The wire
- 01A nationwide cross-sectional study across Spanish community pharmacies enrolled 531 adults, 52.2% treated for obesity and 47.8% for glucose metabolism disorder, finding mean weight loss of 12.17 kg, or 11.71%.
- 02The data give pharmacists real-world benchmarks on anthropometric outcomes, prescribing patterns and digestive adverse reactions outside randomized trial conditions.
- 03Baseline weights were self-reported and unverified against records, and the cross-sectional design cannot establish causation or capture discontinuation over time.
From the source
Read at pubmed.ncbi.nlm.nih.govReal-World Anthropometric Outcomes, Safety, and Use Patterns of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity and Glucose Metabolism Disorder: A Nationwide Multicentre Community Pharmacy Study
Healthcare (Basel, Switzerland) · 2026 Oct 8 · Vergniory-Trueba O, Treceño-Lobato C et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42881794/
